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1. Introduction 
Joint injuries are becoming increasingly common, with young adults between the ages of 18-
44 seeking medical attention for joint sprains, dislocation, fractures, anterior cruciate 
ligament (ACL) and meniscal tears, and others. The cascade of events that follow these joint 
injuries have been shown to increase the risk of post-traumatic osteoarthritis (PTOA) by 20-
50% (Anderson et al,2011). Therefore, understanding biological responses that predispose to 
PTOA should help in determining treatment strategies to delay and/or prevent the 
progression of the disease. Ex vivo and in vivo studies (Anderson et al,2011;Buckwalter et 
al,2004;Furman et al, 2007; Guilak et al,2004; Hurtig et al, 2009) have provided evidence that 
the force and severity of the impact applied to the joint are among the risk factors  involved 
in the development of PTOA. Recent research on the events that follow joint trauma have 
shown chondrocyte death and apoptosis, inflammation (elevation of caspases, selected pro-
inflammatory cytokines, matrix fragments, nitric oxide, reactive oxygen species [ROS], etc.) 
and matrix damage/fragmentation to be early phase responses to injury. Together they lead 
to the development of OA-like focal cartilage lesions characterized by the loss of matrix 
constituents, surface fibrillation, and fissures that if untreated have a tendency to expand 
and progress to fully-blown disease.  
Currently, the only treatments available for joint trauma are surgical interventions, such as 
microfracture, articular chondrocyte transplantation, autografting, allografting, debridement 
and lavage. There are also some experimental approaches that involve engineering of 
cartilage with the use of juvenile cartilage, scaffolds and various polymeric matrices, but 
those are still in development. To the best of our knowledge none of them could regenerate 
normal adult hyaline cartilage that is able to perform required functions, sustain the load 
and integrate with the host tissue. Furthermore, newly repaired tissue, due to its imperfect 
structural organization, may also be more susceptible to re-injury, an important aspect that 
often remains forgotten. Therefore, there is an unmet need in the development of novel 
therapeutic approaches based on the mechanisms that drive the onset and progression of 
PTOA in order to stimulate biologic repair, delay or prevent the need of surgery, or when 
used together, improve the outcome of surgical interventions if biologics are applied prior, 
during, or soon after surgery. Based on our current understanding of the molecular and 
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cellular manifestations of injury the following therapeutic options could be considered for 
PTOA: chondroprotection, anti-inflammatory, matrix protection, and stimulation of matrix 
remodeling with pro-anabolic factors. These and other approaches will be discussed in 
details in the current book chapter.  
2. Joint injuries and the risk of post-traumatic osteoarthritis (PTOA) 
Although joint injuries are not as life threatening as myocardial infarctions and strokes, they 
are similarly life changing. They are progressive and debilitating, with progression often 
leading to OA. Traumatic insult to a joint, as a precursor to OA, has been studied since it 
was first described by Hunter in 1743 (Key,1933). It was reported that 13 to 18% of total hip 
or knee patients had an identifiable acute trauma to the joint (Kern et al,1988). Further 
evidence of joint injury being a major factor in the development and progression of PTOA 
came from the work of Roos, in which it was shown that early onset of OA can occur within 
10 years after injury (Roos et al,1995). With increased social and sport-related activities of 
today’s society there are more and more younger people (18-44 years) who present with the 
evidence of post-traumatic focal cartilage lesions and OA- like changes occurred as a result 
of joint injury. This is in comparison to idiopathic OA, where its prevalence is increased 
with ageing and is more evident after the age of 50 (Anderson et al,2011;Brown et 
al,2006;Dirschl et al,2004;Gelber et al,2000). Approximately 12% of the overall prevalence of 
severe OA is attributable to post-traumatic hip, knee and ankle OA which corresponds to 
about 5.6 million people in the US suffering from PTOA (Brown et al,2006). With such a high 
prevalence of a lifelong nonfatal disability, there is enormous annual socioeconomic burden 
on the health system estimated to be $3.06 billion (Brown et al,2006). These numbers may be 
underestimated because they were based on patients presenting with severe OA that 
required total joint replacement and did not include patients with early or less advanced 
OA. A more recent study in 2008 (Murphy et al,2008) revealed that a history of knee injury 
carried a 56.8% lifetime risk of symptomatic knee OA. 
3. Pathogenesis of PTOA 
The pathogenesis of PTOA is not fully understood, in part due to the lack of correlation 
between the disease progression and the symptoms; therefore, it is difficult to estimate the 
number of individuals suffering from PTOA. Diagnosis is usually based on parameters used to 
diagnose idiopathic OA such as joint pain, visible signs of joint deformity, radiographic 
changes and biochemical tests that detect inflammation. However, many of these may not be 
presented at early stages after joint injury (Brown et al,2006). PTOA is not a unifactorial disease 
and there are a number of factors that could contribute to the onset and progression of PTOA: 
lost structural integrity of menisci and ACL, joint incongruence, lost muscle strength, 
continued physical activity, excessive biomechanical overload of the joint, intra-articular 
inflammation, and others (Furman et al,2006). The key difference between the two types of OA 
is the presence of precipitating insult to the joint in patients that suffer from PTOA versus 
idiopathic OA associated with ageing, genetics, obesity, occupation, bone density, metabolic 
disease, inflammation and abnormal biomechanics. Since it takes years and decades for the 
development of PTOA after injury, aforementioned factors known to contribute to the 
idiopathic OA may also play a role in the progression of PTOA. Regardless what causes PTOA 
it develops as a result of poor intrinsic regenerative ability of hyaline articular cartilage 
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(Anderson et al,2011;Pelletier et al,1998;Sandell et al,2001). In clinical setting, patients with 
signs of PTOA usually present with an advanced form of the disease in which the meniscus, 
ACL and the cartilage have eroded. As a result, there is a reduction in cartilage thickness with 
areas of complete loss and formation of fibrocartilagenous repair tissue. Biomechanically these 
patients have a decreased tensile strength and compressive stiffness (Furman et al,2006). 
The extent of cartilage damage depends on the intensity and force of the impact (Anderson et 
al,2011;Butler et al,2008; Furman et al,2006). The type of damage can be categorized as: a) 
cartilage only disruption characterized by changes in structural components of the matrix and 
chondrocyte death. These may progress to focal lesions. b) Fracturing along the tidemark, in 
which the cartilage tissue above the calcified zone can exhibit blistering and full thickness 
cartilage loss can be seen. c) Fracturing through the calcified cartilage into the subchondral 
plate that can in most severe cases form osteochondral fragments (Anderson et al,2011). 
4. Current clinical treatments for PTOA 
Joint injuries have a high prevalence especially in young individuals and unfortunately, 
predominantly surgical interventions are currently available for their treatment:  
a. Arthroscopic lavaging and debridement (Avouac et al,2010;Reichenbach et al,2010), 
which wash and remove pieces of degenerative cartilage, fibrous tissue and synovial 
fluid full of catabolic mediators that may cause joint inflammation, swelling and 
destruction. The removal of loose debris, cartilage flaps, torn meniscal fragments and 
synovial fluid may provide a temporary relief but does not prevent the generation of 
more fragments and more inflammation. Hence, this method has shown little to no 
evidence of significant improvement in pain relief or restoration of joint function 
(Avouac et al,2010;Reichenbach et al,2010). The arthroscopic nature of this method 
limits its use to patients with small cartilage defects. 
b. Viscosupplementation with hyaluronic acid via intra-articular injections into the knee joint 
potentially improves joint lubrication and may help to restore cartilage. It also provides 
some relief of pain not seen with other analgesics such as ibuprofen or nonsteroidal anti-
inflammatory drugs (NSAIDs) (Iannitti et al,2011;Kappler et al,2010;Migliore et al,2011). 
This approach has been only effective in mild to moderate OA. 
c. Recently, the usage of autologous blood products became a potential breakthrough in 
augmenting joint tissue healing (Anitua et al,2004,2006;Sanchez et al,2009). This new 
method provides cellular and humeral mediators which have been greatly beneficial in 
regenerative processes of cartilage and other connective tissues. Autologous blood 
products are heavily populated with platelets, which have the capacity to release growth 
factors from their ┙-granules (chemokines and newly synthesised metabolites) and thus 
positively influence the tissues with low healing potential. Intra-articular injection of 
platelet concentrate may represent an innovative treatment to improve cartilage 
remodelling. More studies are indicated to understand the mechanism of action and to 
optimize, standardize, and widely implement into the clinic this new technology. 
d. Osteochondral grafting makes up about 10% of surgical procedures available up to date to 
repair cartilage lesions (Cole et al,2009). Unlike procedures that target repair or 
regeneration, osteochondral grafting has garnered significant attention because of its 
ability to replace the lesion with true hyaline cartilage and allow for a relatively short 
recovery period (Convery et al,1972;Horas et al,2003;Nam et al,2004;Shasha et al,2003). 
Osteochondral grafting involves harvesting a cylindrical donor plug of cartilage attached 
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to underlying subchondral bone and implanting the graft into the recipient site covering 
the cartilage lesion. This procedure has a lot of potential for the treatment of isolated 
cartilage defects in young, active patients; however, graft survival is still limited with 
survival rates under 50% after 15 years (Shasha et al,2003). Other problems with grafting 
are the integration with the host cartilage and reduced viability and metabolism of 
residing chondrocytes in case of prolong stored allograft tissue (Kirk et al,2011). 
e. Microfracture and bone marrow stimulation. These surgical options are employed when 
cartilage damage is confined to small focal areas. The damaged cartilage is removed to 
expose and perforate the subchondral bone. This can stimulate new cartilage growth in 
the subchondrol defect through the generation of a fibrin clot and recruitment of bone 
marrow mesenchymal stem cells. The fibrocartilage that covers the full thickness chondral 
lesion does not have the biomechanical strength and resilience of the native cartilage. 
Although this fibrocartilage has been shown to provide relief from the symptoms for 
several years (Miller et al,2004), it does not alter the progression of PTOA as patients 
present with OA symptoms 5 years after microfracture surgery (Miller et al,2004).  In a 
majority of the patients, the size of the cartilage defect increases after microfracture (Von 
Keudell et al,2011). The implantation of collagen membranes over the microfracture in a 
technique referred to as Autologous matrix induced chondrogenesis (AMIC) have been 
used to improve the chondrogenic differentiation of the mesenchymal stem cells (Behrens 
et al,2006) into more hyaline like cartilage. In other efforts to improve cartilage 
regeneration after microfracture, Saw et al (Saw et al,2009) have developed an in vivo 
method in goats that used intra-articular injections of autologous peripheral blood 
progenitor cells and hyaluronic acid. The results have been promising and a clinical pilot 
study has shown regeneration of articular hyaline cartilage (Saw et al,2011). 
f. Autologous chondrocyte implantation (ACI) was first described by Brittberg et al 
(Brittberg et al,1994). Although cartilage regeneration of the defect was observed, 
several serious problems have been associated with this method. 1) It is a two-step 
procedure. 2) The need to create additional defects within the normal and un-affected 
joint for the extraction of autologous chondrocytes. 3) The need for a two-week in vitro 
cell expansion to obtain a sufficient number of chondrocyte to cover and fill the original 
defect. 4) Reduced viability and altered phenotype of autologous cells; and finally, the 
quality and properties of regenerated fibrocartilage (Horas et al,2003).  
g. Articular cartilage regeneration with stem cells is another cell-based cartilage repair 
procedure. Similar in concept to ACI, autologous mesenchymal stem cells have been used 
to decrease knee pain (Kuroda et al,2007). However, for the most part all listed methods 
generate fibrocartilage or a mixture of hyaline-like and fibrocartilage (Kuroda et al,2007). 
h. Knee replacement surgery with a metal shell is often used to treat advanced PTOA in 
patients that show severe destruction of the joint and exhibit increasing joint stiffness 
and pain. However, the knee replacement itself has been associated with chronic pain, 
joint stiffness, post-operative inflammation, and prolong recovery (Gonzalez et al,2004).  
Current surgical approaches are mainly utilized to treat the developed disease, while the 
whole idea of biologic treatment is based on the premise to arrest and/or prevent the onset 
and progression of the disease. Ideally, biologic interventions should be applied immediately 
or soon after the trauma incident. But, in reality patients present with moderate to severe 
PTOA when meniscus and cartilage erosion has already advanced. The lack of satisfactory 
surgical and other therapeutic approaches to successfully restore cartilage structure and 
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function still remains a challenge in current orthopedics. Only few clinical trials have been 
conducted to investigate the efficacy of various classes of therapeutics in PTOA. Therefore, 
advances in our understanding of the mechanisms that govern the development of the disease 
come primarily from in vitro or in vivo animal models of the PTOA.  
5. In vivo and in vitro approaches to study PTOA 
Animal models that resemble human OA pathology have been difficult to develop and 
generally require some surgical insult. In Table 1 we summarized the majority of in vivo and in 
vitro studies that focused on joint trauma and the fate of cartilage after chondral or 
osteochondral damage (Borrelli et al,2003;Clements et al,2004;Green et al,2006a,2006b;Lewis et 
al,2003;Newberry et al,1998;Vener et al,1992). As outlined, this literature consistently points to 
three overlapping phases after acute cartilage injury that include a death/apoptosis phase, an 
inflammatory phase, and a limited repair phase. Studying cellular responses initiated by acute 
injury we identified and characterized a sequence of biologic events (both catabolic and 
anabolic) that cause the progressive joint degeneration leading to PTOA (Anderson et 
al,2011;Bajaj et al,2010;Hurtig et al,2009;Pascual Garrido et al,2009). 
 
Target Therapeutic Agent Reference
Chondroprotection
PI88
Caspase Inhibitors 
( Z-VAD-FMK; Q-VD-Oph; Caspase-3; 
Caspase-9)
Anti-oxidants
iNOS inhibitors 
(L-NAME; L-NIL)
Rotenone
N-acetylcysteine
(Martin et al, 2009); (Phillips&Haut, 2004); 
(Pascual Garrido et al, 2009 ); (Bajaj et al, 2010 )
(Martin et al, 2009); (Pascual Garrido et al, 2009 
); (D'Lima et al, 2006 ); (D'Lima et al, 2001); 
(Huser & Davies 2006) (Lotz, 2010) 
(Kurz et al, 2004)
(Marsh et al, 2002); (Pelletier et al, 1998, 1999, 
2000)
(Goodwin et al, 2010 )
(Martin et al, 2009); (Martin et al, 2009)
Anti-inflammatory IRAP/ IL-1Ra
Anti-TNFα, PEGylated soluble 
TNFα
(Fox & Stephens, 2010); (Frisbie et al, 2002); 
(Evans et al, 2004); (Meijer et al, 2003)
(Zafarullah et al, 2003); (Martel-Pelletier, 1999); 
(Furman et al, 2006); (Fukui et al, 2001); (Evans 
et al, 2004); (Elsaid et al, 2009)
Matrix protection MMP inhibitors / TIMPs
ADAMTS inhibitors (AGG-523)
(Jarvinen et al, 1995); (Murrell et al, 1995) 
(Chockalingam et al, 2011)
(Glasson et al, 2005); (Chockalingam et al, 
2011)
Pro-anabolic, inducers of 
repair
BMPs (BMP-2; BMP-7)
IGF-1
FGF-18
(Hunter et al, 2010); (Hayashi et al, 2008, 2010); 
(Hurtig et al, 2009); (Chubinskaya et al, 2007); 
(Cook et al, 2003); (Badlani et al, 2008)
(Chubinskaya et al, 2011); (Fortier et al, 2002); 
(Im et al, 2003)
(Moore et al, 2005); (Lotz & Kraus, 2010); 
(Ellsworth et al, 2002)
 
Table 1. Potential targets and therapeutic interventions for post-traumatic osteoarthritis.  
iNOS, inducible Nitric oxide synthase; IRAP, interleukin receptor antagonist protein; Anti-
TNF-┙, tumor necrosis factor (TNF)-┙ soluble receptor; MMP, matrix metalloproteinases; 
TIMPs, tissue inhibitors of matrix metalloproteinases; ADAMTS, A Disintegrin And 
Metalloproteinase with ThromboSpondin-like repeats;  BMPs,Bone Morphogenetic Proteins; 
IGF-1, Insulin-like Growth Factor-1; FGF-18, fibroblast growth factor-18; L-NAME,  N-Nitro-
L-arginine methyl ester; L-NIL, N-iminoethyl-L-Lysine; Z-VAD-FMK, benzyloxycarbonyl-
Val-Ala-Asp(OMe) fluoromethylketone; AGG-523, Aggrecanase inhibitor. 
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Cartilage impact models can be divided into two types: impaction to the closed joint, which 
maintains normal joint biology; and open impaction applied directly to the open joint or to 
the surface of articular cartilage explants. Closed impactions have been studied primarily in 
canine, Flemish giant rabbit or mice (Ewers et al,2002,2000b;Newberry et al,1997;Oegema et 
al,1993;Thompson et al,1991). In the canine model, cell death and fractures in the 
subchondral bone and calcified cartilage were observed without full-thickness cracks in the 
cartilage. OA-like degenerative changes were reported at 6 months, but these had stabilized 
by 12 months (Thompson et al,1991). In the rabbit model, the effect of trauma depended on 
the level of stress and varied from cartilage softening with no thickening of subchondral 
bone to cartilage softening accompanied by subchondral bone thickening/remodeling at 4.5 
and 12 months post-trauma. It is not clear whether the damage seen in either of these 
models would progress to OA if sufficient time was given for end-stage OA to become 
apparent. 
Open impact models. In open in vitro and in vivo impact models, the outcome depends on 
the impact forces. Forces above 500 N created more damage in the medial femoral condyle 
of the New Zealand white rabbits than forces below 500 N (Zhang et al,1999). The 
subchondral bone remained intact with only superficial fibrillation; although micro-
structural injuries may have been present. When an impact was applied on an 
unconstrained plug of cartilage attached to subchondral bone, a stress of 25MPa at 25% 
strain disrupted chondrocytes and the cartilage matrix (Ewers et al,2001). Since chondrocyte 
death would eventually lead to matrix loss (Simon et al,1976), cell death has become the 
focus of cartilage trauma research and has been primarily studied in vitro in the open impact 
models (Ewers et al,2001;Jeffrey et al,1995;Repo et al,1977;Silyn-Roberts et al,1990;Torzilli et 
al,1999). Cell death was observed around cracks (Repo et al,1977) and there was a linear 
relationship between cell death and impact energy with stress levels up to 200 MPa (Jeffrey 
et al,1995). Cell death was already observed in the surface layer at 15-20 MPa, while 
extensive cell death in the deep layer was evident at higher levels (Torzilli et al,1999). In an 
open joint impact model with the impaction level of 25 MPa it has been shown (Hurtig et 
al,2009)that, if untreated, impact injuries progress to OA-like lesions radially from the center 
of  impaction and present the loss of cartilage matrix components, surface fibrillation and 
fissures typical for OA-like pathology. 
6. Immediate cellular responses to acute trauma and intervention strategies 
The immediate responses that occur after joint trauma involve cell death by necrosis and 
apoptosis, activation of various catabolic events (inflammation, release of free radicals, 
nitric oxide [NO], proteinases, etc) and mechanical and enzymatic  matrix disruption 
characterized by collagen fragmentation, loss of major matrix components (proteoglycan, 
hyaluronan, and other), and matrix structural disorganization. Often joint trauma is also 
accompanied by intra-articular bleeding. All these events identify intervention 
strategies that are based on specific molecular and metabolic pathways. Strategies that 
prevent post-traumatic cartilage degeneration and loss of cartilage and joint homeostasis 
would be valuable; and there is considerable experimental evidence that this goal may be 
attainable (Boileau et al,2002;El Hajjaji et al,2004;Ewers et al,2000a;Jovanovic et 
al,2001;Myers et al,1999;Pelletier et al,2000b;Phillips et al,2004;Smith et al,1999). The ideal 
therapy must be multi-varied and include anabolic effects on chondrocyte metabolism 
www.intechopen.com
 Post-Traumatic Osteoarthritis: Biologic Approaches to Treatment 
 
239 
and stimulation of intrinsic repair while protecting integrity of cell membrane and 
inhibiting catabolic pathways that lead to chondrocyte death and matrix loss. In other 
words, the following are the key mechanisms that should be considered while 
developing biologic intervention therapies: 1) Chondroprotection; 2) Anti-inflammatory; 
3) Matrix protection; and 4) Pro-anabolic, inducers of repair (Table 1).  They are 
discussed below in more details. 
7. Chondrocyte death 
It has been well documented that cell death is the first response in all injuries that 
involve blunt trauma or direct insult (impaction, injurious compression, wound creation, 
etc) to cartilage surface or the entire joint. The role of cell death in PTOA has been widely 
studied using in vivo animal models, ex vivo animal and human models and in vitro 
culture approaches with cartilage from different species including humans (Table 2). 
Chondrocyte death in response to a single impact was first reported in the 1970’s (Finlay 
et al,1978;Repo et al,1977) and was extensively studied in the last few decades. It was 
shown that controlled single impacts of 15-21 MPa on bovine cartilage explants resulted 
in chondrocyte death within 24 hours after the injury (Oegema et al,1993; Torzilli et 
al,1999). 
This phenomena has been confirmed in multiple studies using cartilage from different 
species and applying various forces (15-53MPa) (Newberry et al,1998; Thompson,1975; 
Lewis et al,2003;Oegema et al, 1993; D'Lima et al,2001b;Ewers et al,2000b,2001,2002; Jeffrey 
et al,1995; Bolam et al,2006; Hurtig et al,2009; Beecher et al,2007; Pascual Garrido et al,2009; 
Bajaj et al,2010; Huser et al,2006a). The level of cell death and the depth of damage were 
proportional to the energy of the impact (Huser et al,2006a; Bolam et al,2006 ). These 
observations of the impact induced chondrocyte death in bovine, rabbit, canine, equine, and 
human cartilage point towards a general mechanism of trauma-mediated effects suggesting 
that cellular responses to injury could be studied in species that are readily available as 
models of PTOA.  In the PTOA models chondrocytes could die by two mechanisms, necrosis 
and apoptosis. Necrosis occurs as a direct effect of impact/injury on the cell resulting in the 
disruption of the cellular membrane and loss of its integrity as well as the damage of the 
intracellular organelles.  This type of death occurs immediately after the insult and is 
difficult to prevent in the PTOA models. Necrotic cell death also leads to the release of 
calcium, free radicals, nitric oxide, and the activation of intracellular catabolic mediators, 
including caspases, interleukins, proteinases, etc. All of them are capable of triggering the 
process called “apoptosis” leading to the programmed cell death.  This second type of death 
could be prevented and arrested by using targeted therapeutics. For the most part, in the 
studies on PTOA types of death are not distinguished. Good examples that address both 
mechanisms are in vitro and in vivo studies with canine, sheep, or human cartilages (Chen et 
al,2001; Bajaj et al,2010;Hurtig et al,2009;Pascual Garrido et al,2009). Importantly, necrosis 
and apoptosis are usually spaced out in time, as it was reported for canine cartilage (Chen et 
al,2001), where a cyclic impaction induced necrosis during the first 4 hours after the impact, 
while apoptosis was seen 48 hours after the impact. As was already stated, the level of cell 
death depends upon the energy of the impact, but   cell death is always observed at the 
surface and in the superficial cartilage zone; it is less pronounced in the middle and deep 
layers of cartilage (Beecher et al,2007;Pascual Garrido et al,2009).  
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Species Model Impact Follow-up Major parameters Ref
In Vitro Models
Human cart /bone in vitro impact drop-tower device up to 25N Cell survival (Repo & Finkay, 1977)
in vitro impact 25 MPa Cell death (Silyn-Roberts & Broom, 1990)
Canine in vitro injury 1-2.4 kN Immediate Gross evaluation, histology, EM (Vener et al, 1992)
Bovine cart w/o bone impact load in vitro 100g-1kg/5-50cm height 3-15 days culture Cell survival, Matrix integrity, EM (Jeffrey et al, 1995)
Bovine cart/bone In vitro impact 50-75 MPa force displacement curves, histology, Water content, EM (Borrelli et al, 1997)
Rabbit In vitro impact low and high intensity impact immediate Indentation, histology (Newberry et al, 1998)
Bovine in vitro impact 15-20 MPa Cell viability, water content (Torzilli et al, 1999)
Rabbit impact load 96 hr apoptosis, GAG release (D'Lima et al, 2001a)
Human in vitro impact 14 MPa 0-7, 24,48, 96 hrs apoptosis, GAG release (D'Lima et al, 2001b)
Porcine patella's/bone blunt low impact 0.06, 0.1, 0.2 J Immediate Cell death, EM (Duda  et al, 2001)
Bovine patella acute impact in vitro 53 MPa 18hr-5 days Cell viability (Lewis et al, 2003)
Canine cyclic impacts 21 days apoptosis, GAG  and NO release (Clements et al, 2004)
Bovine cart w/o bone single impact 100g/10cm high drop tower 3 min, 20 min Cell viability, LDH levels (Bush et al, 2005)
Canine impact ex vivo 20-25 MPa 7 days Cell viability, NO, ICAM-1 (Green et al, 2006)
Equine cart w/o bone single-impact load 130 MPa 48 hr cell death, apoptosis, GAGs (Huser et al, 2006)
Porcine single impact 2, 8, 14 MPa 0,3,7, 14 days Cell viability, Histology, Immunohistochem (Otsuki et al, 2008)
Bovine cyclic impacts 25 MPa 7, 14, 21 days PG synthesis, cell viability (Wei et al, 2008)
Porcine cyclic impacts 5, 30-40MPa 4,24hr
Viability, lactate assay, PG synthesis, gene expression of 
MMP3,AGG (Ramakrishnan et al, 2009)
Human Single impact 600N 0,2,7,14 days Viability, apoptosis, histology (Pascual-Garrido  et al, 2009)
Bovine single impact 7J/cm2,14J/cm2 48hr Viability,GAG content (Martin et al, 2009)
Bovine single impact 14J/cm2 20min, 1,3,6,12,24,48hr, Histology,viability,PG synthesis, confocal (Ding et al, 2010)
Human single impact 1Ns 20min, 1,24hr Western blots for ERK, Jun, JNK,P38, Stat3, GSK3 (Bajaj et al, 2010)
Bovine single impact 20MPa 10,20,30,40,50mins, 1,3,6,24,48hr Histology, viability,SOD production (Goodwin et al, 2010)
Bovine single impact 0, 0.35,0.71, 1.07, 1.43 J 1, 4 days Viability (Szczodry et al, 2011)
In Vitro Compression Model
Bovine unconfined compression 17MPa over night Histology (Kurz et al 2004)
Bovine cart w/o bone unconfined compression 40-900 MPa/s 4 days Cell death, GAGs (Ewers et al, 2001)
Bovine, Human cart w/o bone mechanical load apoptosis, GAG release (D'Lima et al, 2001a)
Rabbits acute Osteochondral injury 2 mm drill 4 days Apoptosis (Costouros et al, 2003)
Bovine mechanical load in vitro Immediate or 7 day culture PCR:18S,b-actin,b-2-Microglobulin (Lee et al, 2005)
Calves mechanical load 50% Strain 4-16 days Aggrecanase immunohistochem, AGG western, (Lee et al, 2006)
NITEGE, anti-G1
Bovine mechanical load 35MPa 0,24,48,72, 96, 120 hrs cell proliferation, PG synthesis, ERK expression (Ryan et al, 2009)
Ex Vivo Models
Canine in vivo surgically-created OA ex vivo 12 wks post op viability, effect of caspase, COX and iNOS inhibitors (Pelletier et al, 2001)
In Vivo Models
Canine in vivo surgically-created trauma 1-110 wks post-op acid hydrolase (Thompson, 1975)
Canine closed-joint impact in vivo 2000 N 2,12,24,52 wks Histology, Immunohistochemistry (Pickvance et al, 1993)
Fibronectin, 3-B-3, IL-1b, TNF-a
Canine transarticular load in vivo 2000 N 2,8,16, 36, 52 wks Scanning EM, histology, MRI (Thompson et al 1993)
Canine closed impact 2wks, 3 mo IL-1, TNF, GAG (Oegema et al, 1993)
Canine impact in vivo 6,12mo Cell viability (Thompson et al 1991)
Rabbit Impact in vivo up to 12 mo Biomechanics, histology (Newberry et al, 1997)
Rabbit impact 120N Immediate structural changes (Borrelli et al, 1997)
Canine in vivo surgically-created OA 10wks post op Histology, MMP activity, IL-1β PGE, NO assay (Pelletier JP et al, 1998)
Canine in vivo surgically-created OA 12wks post op Gross evaluation, histology (Pelletier et al, 1999)
Rabbit closed impact 10KHz 0,4.5,12 mo post-op stress , histology (Ewers et al, 2000)
Rabbit closed impact 5ms/peak or 50 ms/peak histology, bone softening (Ewers et al, 2002)
Equine in vivo surgically-created trauma 48 hr, 7, 14,21,28,35 and 70 day post op Histology, GAG content, IL-1Ra, PGE (Frisbie et al, 2002)
Rabbit impact in vivo Low and high impact Immediate Apoptosis, EM, light microscopy (Borrelli et al, 2003)
Canine impact in vivo 18-25 MPa 1,2,4,8,12,116,20,24 wks TNF, blood, NO, MMPs, GAG (Green et al, 2006)
Rabbit in vivo surgically-created OA 9 wks post op Histology, immunohistochemistry (D'Lima et al, 2006)
Mouse closed fracture 2,4,8,50wks Histology, Micro CT (Furman et al, 2007)
Rabbit in vivo surgically-created trauma 4,8,12 wks post op Histology, immunohistochemistry, micro CT (Hayashi et al, 2008)
Effects of intra articular BMP7 injections
Goat in vivo surgically-created defects Full thickness chondral defects 42 wks post op Histology, immunhistochemistry (Saw KY et al, 2009)
Goat open joint impact 25-MPa 90, 118, and 187 days Histology, apoptosis, GAG, leucocytes (Hurtig et al, 2009)
Rabbit open joint single impact 4350g(low); 4900g(high) 0,1,6 mo Histology, Immunohistochemistry, Viability (Borrelli et al, 2009)
Mouse in vivo surgically-created trauma 4 -8wks post-op Aggrecan, histology (Little et al, 2009)
Rabbit open joint Single impact 3.76MPa 4 day post op Gross evaluation, viability (Isaac et al, 2010)
Sheep partial thickness articular cartilage lesion 12wks Histology, GAG content, Collagen II, NO, IL-1β (Kaplan et al. 2011)
Rat in vivo surgically-created OA 4day, 1,2,3,5,8 wks Aggrecan, (Chockalingam et al, 2011)  
Table 2. In vivo, ex vivo, and in vitro modeling of PTOA. GAG, glycosaminoglycan; PGE2, 
prostaglandin E2; EM, extracellular matrix; NO, nitric oxide; PG, proteoglycan; TNF-┙, 
tumor necrosis factor (TNF)-┙; MMP, matrix metalloproteinases; ADAMTS, A Disintegrin 
And Metalloproteinase with ThromboSpondin-like repeats; BMPs,Bone morphogenetic 
proteins; IGF-1, Insulin-like Growth Factor-1; IL, Interleukin; Micro CT, micro computed 
tomography. 
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Every model has its advantages and limitations, but each provides important information 
adding to our understanding of the PTOA. Studying the cartilage explants out of their joint 
environment eliminates the external influences that cartilage would experience in its natural 
environment. Factors such as weight bearing, vascularization, fluid dynamics of the joint 
and the biomechanics of the supporting tissue cannot be controlled in the in vitro system, 
but it provides an opportunity to distinguish truly cartilage responses to trauma without 
other contributing mechanisms. On the flip side, it makes interpretation of results and 
extrapolation to actual clinical situations more challenging. Investigating cellular events 
using humans is almost impossible due to the nature of experimental approaches and end 
measures. Furthermore, patients come to see the doctor only when pain and signs of 
degenerative changes have been already developed, which eliminates the option of studying 
early cellular responses to trauma. In order to overcome some of these limitations in vivo 
animal models have been employed. Unfortunately, many PTOA studies are conducted on 
rodents or rabbits (Beecher et al,2007;D'Lima et al,2001c;Guilak et al,2004;Isaac et al,2010), 
the animals that either have a tendency to self-repair or are far from resembling human joint 
structure and biomechanics.  In all these models cell death by necrosis and apoptosis was 
the most prominent feature, though the degree of death varied between the models and the 
energy of the impact (Beecher et al,2007;D'Lima et al,2001c;Milentijevic et al,2005). 
Chondrocyte death and superficial matrix damage were always observed immediately after 
impaction. The changes that were reported 3 to 52 weeks post impactions were those 
typically seen in early and late stage osteoarthritis, such as matrix damage, chondrocytes 
death and proteoglycan loss (Milentijevic et al,2005;Rundell et al,2005), and at later stages, 
characteristic cartilage fibrillation, clone formation, matrix disorganization, and joint space 
narrowing (Hurtig et al,2009).  All these models indicate that even smaller forces could be 
sufficient to initiate cell necrosis and higher forces may be needed to initiate massive 
apoptosis (D'Lima et al,2001b;Milentijevic et al,2005;Rundell et al,2005). The majority of 
studies used a drop-tower device in an open joint injury models.  Borrelli et al (Borrelli et 
al,2003) used a pendulum type apparatus to apply a rapid impact to the articular surface of 
the femoral condyle.  We used a pneumatically controlled impactor in our studies to 
generate cartilage damage (Bajaj et al,2010;Pascual Garrido et al,2009; Hurtig et al,2009). 
Common injuries, such as sports or vehicular, are usually attained in a closed system. 
Hence, studying open joint impaction may not necessarily reflect real clinical scenario.  
Therefore, investigating chondrocyte responses that occur in a closed fracturing system 
could become more relevant, especially since Gaber et al (Gaber et al,2009) also observed 
significant chondrocyte death after a mid- diaphyseal closed fracture of the tibia.   
In summary, in all PTOA models significant chondrocyte death occurs as earlier as 4 hours 
after the impact and persists for up to 48 hours. If left untreated, it leads to another 
mechanism of cell death, apoptosis and, eventually with time the cartilage develops OA-like 
changes. Consequently, therapeutic strategies aimed at minimizing the results of mechanical 
stress during the early stages post injury may help to preserve structural integrity of 
cartilage and slow or prevent the development of PTOA.  
8. Chondroprotection as an early stage therapy  
Since cell death is the first response in all injuries, the most obvious approach is to protect 
the cells and promote their survival and viability. Chondroprotection could be achieved via 
targeting different mechanisms: cell membrane protection, anti-oxidant therapy, 
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mitochondria protection, inhibition of NO release, inhibition of apoptosis through the 
inhibition of caspase signaling, inhibition of calcium quenching, etc. These approaches are 
addressed below.  
As mentioned above, there are two major mechanisms of cell death: necrosis, in which fluid 
uptake increases causing the cell to swell and rupture resulting in the release of the 
intracellular contents that incites an inflammatory cascade; and apoptosis, in which there is 
a chromatin condensation, DNA fragmentation, cell shrinkage, membrane blebbing that 
cause the cell to self-destruct. Two cellular pathways have been identified in the apoptotic 
signaling, the extrinsic pathway that involves the Fas receptor pathway and the intrinsic 
pathway that involves the mitochondrial pathway (Borrelli,2006). Oxygen and reactive 
oxygen species (ROS) have a role in cartilage homeostasis and are involved in chondrocyte 
activation, proliferation and matrix remodeling (Henrotin et al,2003). In excess amounts, 
they induce chondrocyte death and matrix degradation. Mechanical injury has been 
associated with an increase in production of ROS (Henrotin et al,2003) and  decreased 
antioxidant capacity (Martin et al,2004), which becomes insufficient once structural and 
functional cartilage damage occurred. The use of exogenous antioxidants, such as vitamin E, 
N-acetyl-L-cysteine (NAC) and superoxide dismutase have the potential to protect the 
chondrocytes from the elevated oxidants. Beecher et al (Beecher et al,2007) have shown that 
pre-treatment with antioxidants can significantly increase chondrocyte survival up to 40-
80% in the superficial zone and up to 53-80% in the middle zone. In their study, cartilage 
explants from non-osteoarthritic human cadaver ankle were pre-treated with NAC, 
superoxide dismutase or vitamin E before cyclic impaction of either 2MPa or 5MPa was 
applied. Pre-treatments with NAC and superoxide dismutase were the most effective at 
preventing chondrocyte death, when forces of 5MPa were applied. Although these finding 
are promising in showing that human chondrocyte survival can be attained by the treatment 
with antioxidants, the timing of the antioxidant treatment is not practical, because most joint 
injuries occur without advance warning. This approach may be valuable when antioxidants 
are either injected intra-articularly or applied during surgery, when the joint area that 
undergoes surgical intervention is pretreated with the antioxidants.  By the time of surgery, 
which usually takes place much after the injury, the window of opportunity for antioxidant 
therapy could have been missed. In a similar study by Martin et al (Martin et al,2009) bovine 
osteochondral explants subjected to a single blunt end impact were treated with NAC, 
vitamin E, poloxamer 188 (P188) or Z-VAD-FMK after impaction. The agents were 
administered either immediately after injury or were delayed by 4 hours. Immediate 
treatment with NAC improved chondrocyte viability by up to 74%, while delayed treatment 
also promoted cell survival, but to a lesser extent, 59%, though still being relatively high. Z-
VAD-FMK, a caspase inhibitor and anti-apoptotic agent, improved chondrocyte survival to 
the level of delayed NAC treatment. Vitamin E and P188 did not significantly increase cell 
survival. In our studies with the human cartilage ex vivo injury model, NAC was effective 
only while it was present in culture media (first 48 hours). It promoted cell survival and 
inhibited apoptosis in the superficial layer, which was two times lower in the NAC treated 
explants than in the untreated control. However, after NAC removal, apoptosis returned to 
the levels of untreated impacted control. Similar observations were found for PG synthesis, 
which was elevated by two-fold at day 2 under the NAC treatment, but declined to the 
untreated controls levels as the agent was removed. Adjacent, not impacted areas remained 
protected by NAC treatment and cell viability was comparable to that of the non-impacted 
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controls. Though in our experiments NAC was effective in protecting the cells, it was 
ineffective in providing the protection for cartilage matrix integrity. Similarly to Beecher et 
al,  Kurz et al compared the pre-treatment option versus post-injury treatment to see 
whether pre-treatment with antioxidants could enhance chondrocyte viability (Kurz et 
al,2004),  though clinical relevance of this approach remains to be justified. Superoxide 
dismutase reduced apoptosis in a dose dependent manner with complete inhibition of 
apoptosis when the highest dose of 2.5µM was used, while vitamin E had no effect. Despite 
the efforts,   a consensus cannot be achieved on whether the treatment with antioxidants 
prior to or after the injury has a beneficial effect in enhancing cell survival (Beecher et 
al,2007;Kurz et al,2004;Martin et al,2009).  1) Different time points and different methods 
were used to assess cell viability; 2) no distinction was made between necrosis and 
apoptosis; 3) different species were often used; and 4) distinct responses to the same agent 
were observed. Differences in responses can be attributed to species- and model-specific 
distinctions. It has been suggested that blunt versus cyclic impaction model may trigger 
distinct cellular responses and induce, for example, lipid peroxidation that has a damaging 
effect on plasma membrane (Beecher et al,2007). Therefore, accumulation of Vitamin E in the 
plasma membrane could have a protective effect (Claassen et al,2005). This is also supported 
by the fact that Vitamin E was the most active within the first 4 hours.  Together these data 
indicate an anti-necrotic mechanism of Vitamin E activity.  Despite the differences, above 
referenced studies generate one important message: a window of opportunity for treatment 
does exist and mechanism-based timely delivery of biologics could provide necessary 
protection in post-traumatic degenerative events.  
The beneficial effects of ROS scavenger NAC (a powerful hydroxyl and hypochlorous 
radical scavenger) and superoxide dismutase on chondrocyte survival implicate 
chondrocyte death by apoptosis being secondary to the production of ROS, although the 
source of ROS excess remains unclear.  Chondrocyte survival experiments with superoxide 
dismutase suggest a role for the mitochondria in early cellular responses to injury. 
Rotenone, an agent that suppresses the release of superoxide from the mitochondria, has 
been tested to confirm the role of the mitochondrial electron transport chain in the 
production of ROS (Goodwin et al,2010). Although rotenone significantly reduced 
chondrocyte death by more than 40% when administered 2 hours post injury (Goodwin et 
al,2010), it is unsuitable for an in vivo use due to its high cellular toxicity. Accepting the 
importance of the mitochondria in ROS release, factors that control mitochondrial 
depolarization have to be considered. Furthermore, it has been shown that injury increases 
intracellular cytoplasmic calcium due to its release by the endoplasmic reticulum. This leads 
to depolarization of the mitochondrial membrane, which is associated with the release of 
cytochrome C, caspase dependent apoptosis and Bcl-2 degradation (Huser et al,2007). 
Altered intracellular calcium homeostasis has been implied in chondrocyte death (Browning 
et al,2004;Ohashi et al,2006) and studies with calcium chelating agents have shown 
significant reduction in chondrocyte death (Huser et al,2007). Thus, calcium quenching 
inhibitors may have therapeutic value, although the mechanism between the mechanical 
impact and the cytoplasmic calcium increase remains to be understood. 
NO and superoxide anion are the two main ROS produced by the chondrocyte (Hiran et 
al,1997;Moulton et al,1997). NO in the chondrocyte is synthesized by endothelial nitric oxide 
synthase (eNOS) or inducible nitric oxide synthase (iNOS) (Henrotin et al,2003) that are 
reportedly regulated by growth factors, cytokines and endotoxins (Henrotin et al,2003). 
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Factors such as Tumor Necrosis Factor (TNF)-┙, Interleukin (IL)-┚, Interferon (INF)-┛ and 
Lipopolysaccharides (LPS) stimulate NO production and Transforming Growth Factor 
(TGF)-┚, IL-4, IL-10 and IL-13 inhibit NO production (Henrotin et al,2003). NO has been 
shown to be up-regulated after trauma and to possess cartilage degradative properties, 
which suggests a potential role for iNOS inhibitors in matrix protection. Evidence for 
chondroprotective effect of NO inhibition comes from studies by Beecher et al (Beecher et 
al,2007), where human cartilage explants, were pre-treated with the nitric oxide synthase 
inhibitor N-Nitro-L-arginine methyl ester (L-NAME) before cyclic impaction loads. In 
treated explants cell survival was considerably higher (82-90%) in the superficial and middle 
layers compared to the 40-53% in the same areas of the untreated explants. The mechanism, 
through which L-NAME exhibited its anti-apoptotic effect, is thought to be via interference 
with the IL-1┚ pathway (Marsh et al,2002;Pelletier et al,1999,1998). In an in vivo canine OA 
model, Pelletier et al (Pelletier et al,1999,2000a) tested the effect of two concentrations of 
another iNOS inhibitor, N-iminoethyl-L-Lysine (L-NIL). The dogs that received the higher 
dose of L-NIL (10mg/kg/day) showed marked decrease in Tunel-positive chondrocytes and 
macroscopically and histologically their cartilage lesions were less severely affected by the 
OA-like changes than the placebo treated dogs. In addition, a reduced level of caspase 3 and 
MMP activity was found in the L-NIL treated dogs (Pelletier et al,1998,2000a). These data 
suggest that iNOS inhibitors reduce the progression of PTOA through the caspase 3 
mediated inhibition of apoptosis that results in the diminished MMP activity (Pelletier et 
al,1998,2000a).  
Apoptosis is one of the main causes of chondrocyte death after mechanical injury (Chen et 
al,2001;D'Lima et al,2001a; Borrelli,2006), which is mediated by a complex proteolytic system 
known as the cysteinyl aspartate-specific proteases (caspases). D’Lima et al have 
successfully demonstrated that caspase inhibitors reduce the severity of cartilage lesion in 
an in vivo rabbit OA model. Using intra-articular injections of the pan caspase inhibitor Z-
VAD-FMK (benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethylketone), a cell permeable 
fluoromethylketone, the authors demonstrated reduced cartilage degradation, reduced 
activity of caspase 3 and reduced p85 fragment suggesting that this broad spectrum caspase 
inhibitor prevents apoptosis and slows the disease progression. The effect of Z-VAD-FMK 
has also been studied in  full thickness human cartilage explants subjected to  single impacts 
of relatively low stress, 14MPa (D'Lima et al,2001a). These results were reliably reproduced 
in several other types of injury (static compression and blunt impact) applied to cartilage 
from different species (bovine, rabbit, equine and human) (Huser et al,2006a;Huser et 
al,2006b). However, in our studies with human cartilage  impact induced by a higher stress, 
25-30MPa, the effect of caspase inhibitors (inhibitors of caspase 3 & 9;(Pascual Garrido et 
al,2009) or pan-caspase inhibitors (Z -VAD-FMK or Q -VD-OPh)), was not as pronounced. In 
a 14-day follow-up study we found that caspase 3 inhibitor temporarily halted cartilage 
degenerative changes, while caspase 9 inhibitor was ineffective.  Pan caspase inhibitors, 
contrary to studies of others (D'Lima et al,2001c;Huser et al,2006a;Huser et al,2006b), in our 
acute injury model on human explants, were not able to inhibit apoptosis. Yet the cells that 
survived impaction showed elevated PG synthesis after a treatment with caspase inhibitors. 
This resulted in preservation of matrix integrity (low Mankin score) especially in the areas 
adjacent to the impact. Both pan-caspase inhibitors demonstrated similar efficacy.  
Despite a wide range of effects, evidence suggests that caspase inhibitors could be and 
should be considered for targeted therapeutic intervention in PTOA, if they are utilized 
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immediately or soon after joint injury before the fully-blown apoptotic cascade takes 
place.  
Another way to fight cell death is  physical protection of cell membrane integrity (Duke et 
al,1996). Therefore,  a number of laboratories (including ours) focused on the use of 
poloxamer 188 (P188), a nontoxic nonionic surfactant that has a hydrophilic and a 
hydrophobic center, similar to the lipid bilayer composition (Bajaj et al,2010;Isaac et 
al,2010;Martin et al,2009;Pascual Garrido et al,2009;Phillips et al,2004).  It has been suggested 
that surfactant molecules, (i.e. P188), insert into the membrane to restore the cell membrane 
integrity post injury, protecting the cell form subsequent catabolic activation. 
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Fig. 1. Diagrammatic representation of P188 surfactant restoring membrane integrity 
The role of P188 in bovine chondroprotection was first discovered by the group of Haut 
(Phillips et al,2004) who showed that P188 statistically reduced the level of apoptosis in the 
ex vivo blunt impaction model. In follow-up studies, an increase in chondrocyte viability 
with early P188 treatment in  short- and long-term has been also documented in vivo in 
rabbits (Isaac et al,2010). We undertook a more comprehensive approach in an attempt to 
understand the mechanism of P188 action. We demonstrated that P188 was superior to 
inhibitors of caspase 3 and 9 in promoting cell survival after acute injury (Pascual Garrido et 
al, 2009). We also found that a single treatment with P188 (8mg/ml; added immediately 
after injury) was able to inhibit cell death by necrosis and apoptosis and, more importantly, 
was able to prevent horizontal and longitudinal spread of cell death to the areas that were 
not directly affected by the impaction. Though P188 was present in the explant culture only 
for 48 hours, the effect was sustainable for 7 of 14 days. Furthermore, we identified the 
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mechanisms through which P188 exhibited its effect (Bajaj et al,2010). Earlier, the role for 
mitogen-activated protein kinases (MAPKs), c-Jun-N-terminal kinase and p38, in P188 
mediated effects was implied in neural tissue (Serbest et al,2006). We found that among the 
mechanisms, through which the surfactant directly or indirectly inhibited cell death by 
apoptosis and prevented its expansion, was the inhibition of the IL-6 signaling pathway. 
Specifically, phosphorylation of key mediators of the IL-6 pathway, Stat1, Stat3, and p38, 
was significantly inhibited or prevented. Furthermore, glycogen synthase kinase 3 (GSK3) 
signaling involved in apoptosis was also inhibited. Our data, both biochemical and 
histological, suggest that p38 kinase may act up-stream of Stats signaling; activation of p38 
kinase as a result of injury, may be partially responsible for initiation of IL-6/Stats mediated 
catabolic events. A single treatment with P188 blocked phosphorylation of Stats as well as 
their translocation in to the nucleus, thus potentially preventing transcription of catabolic 
genes. Furthermore, the role of p38 in injury-induced catabolic responses was further 
verified by the application of specific synthetic p38 inhibitor confirming previous data 
(Serbest et al,2006). Treatment with p38 inhibitor not only inhibited the IL-6 pathway, but 
also promoted cell survival by reducing apoptotic cell death. In addition, we observed an 
inhibitory effect of P188 on Vascular Endothelial Growth Factor and Monocyte Chemotactic 
Protein-1 and a stimulatory effect on IL-7 and especially IL-12, effects that remain to be 
explained. Stimulation of IL-12 may indicate another anabolic response that has not been 
widely explored in cartilage; IL-12 is an important regulatory cytokine that functions 
centrally in the initiation and regulation of cellular immune responses. Because a single 
treatment with P188 lasted only for the first 7 days, we explored multiple applications, 
adding fresh agent to the culture every 48 hours to sustain its presence for the duration of 
the experiments. Multiple treatments with P188 were not superior to its single application, 
suggesting that the primary mechanism of P188 activity is sealing the cellular membrane, 
which prevents trauma-induced cell necrosis and thus the release of catabolic mediators by 
necrotic cells. Treatment with P188 prior to impaction was also ineffective, pointing to the 
role of this agent in repair/restoration of the membrane that was damaged. 
In summary, chondroprotective therapy should be seen as the earliest possible approach to 
treat cartilage tissue post-injury. Chondroprotection has a high potential in the development 
of targeted biologic interventions in PTOA, because when chondrocyte death is reduced and 
cartilage cellularity is preserved, there are more chances for the remaining cells to initiate 
anabolic responses to prevent the expansion of degenerative changes and to remodel 
damaged matrix.  
9. Inhibition of pro-inflammatory mediators as early biologic treatment in 
PTOA 
There are three major anti-catabolic interventions that could be considered at the present 
time: NAC as an antioxidant (described in details above), interleukin-1 receptor antagonist 
(IRAP), and TNF-┙ antagonist. NAC inhibits activation of c-Jun N-terminal kinase, p38 MAP 
kinase, redox-sensitive activating protein-1 and NF-B transcription factor activities 
regulating expression of numerous genes. NAC can also prevent apoptosis and promote cell 
survival by activating extracellular signal-regulated kinase pathway (Zafarullah et al,2003). 
Interleukin-1 (IL-1) and tumor necrosis factor (TNF)-┙ are the most studied cytokines in 
post-traumatic OA (Evans et al,2004;Fukui et al,2001;Furman et al,2006;Guilak et al,2004). 
Both are potent activators of cartilage degradation (Martel-Pelletier,1999) and their activity 
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has been significantly increased after acute injury. The levels of these mediators are shown 
to correlate with the disease severity (Lotz et al,2010;Marks et al,2005). Studies have also 
reported that IL-6, IL-8 and IL-10 (Bajaj et al,2010; Irie et al,2003;Perl et al,2003) play a role in 
cartilage loss and the progression of PTOA (Furman et al,2006).The increased expression of 
these cytokines is attributed to the stressed chondrocytes, synoviocytes and infiltrating 
inflammatory cells. We documented an elevation of IL-6, TNF-┙, basic fibroblast growth 
factor, and other cytokines as early cellular responses to injury (Anderson et al,2011;Bajaj et 
al,2010). 
Currently, the most effective approaches to inhibit activity of catabolic cytokines are the 
ones that could interfere with their signaling: receptor blockers, neutralizing monoclonal 
antibodies, soluble receptors, receptor antagonists, extracellular and intracellular binding 
proteins, as well as various intracellular repressors and cofactors that prevent the 
transcription of catabolic genes. IL-1 activity is mediated by its binding to specific IL-1 
receptor (IL-1R). Therefore, the antagonist of the IL-1 receptor called interleukin receptor 
antagonist protein (IRAP) or IL-RA competes for binding to IL-1 and thus prevents the 
activation of IL-1 signaling. IRAP has been studied in the in vivo OA equine model (Frisbie 
et al,2002), where Ad-EqIL-1Ra was injected intra-articularly.  Clinical observation based on 
pain (lameness) and radiographic examination showed significant improvement in treated 
horses compared to the untreated horses. Histological examination revealed significant 
reduction in subintimal edema, joint fibrillation, and chondrocyte necrosis in horses treated 
with IL-1Ra. Significant, improvement with IL-1Ra treatment seen in the equine model 
strongly supports its potential use in clinics. Methods have been developed to generate 
autologous conditioned serum with enriched endogenous IL-1Ra (Orthokine) (Meijer et 
al,2003) that could be injected into the joint. Preliminary clinical data have shown that intra-
articular injections of Orthokine can improve the clinical signs and symptoms of OA such as 
a reduction in pain and increase in joint function (Fox et al,2010). Whether these methods 
are chondroprotective or alter the progression of disease is still being investigated. 
Recombinant IL-1Ra has been used in clinical trials in rheumatoid arthritis, sepsis and graft 
versus host disease (Evans et al,2004). We investigated whether recombinant IL-RA could 
inhibit cell death and thus affect cartilage metabolism in the ankle cartilage ex vivo acute 
injury model. 100ng/ml IL-RA increased the percentage of live cells by two-fold in the 
superficial layer of the impacted tissue compared with the untreated control; while a low 
dose of IL-RA (20ng/ml) was ineffective. The effect on apoptosis of both concentrations was 
negligible. Although ineffective in promoting cell survival, a lower concentration of IL-RA 
stimulated PG synthesis by three-fold. Normal histological pattern of IL-RA treated samples 
was observed only while the agent was present in culture. As IL-RA was removed, loss of 
Safranin O staining and depletion of proteoglycan became apparent.  
Another cytokine involved in cartilage loss of PTOA is tumor necrosis factor (TNF)-┙ 
(Sandell et al,2001). Antagonists of IL-1 and TNF-┙, namely, IRAP and the PEGylated 
soluble TNF-┙ receptor I, alone and/or in combination, down-regulated MMP-1, MMP-3, 
and MMP-13 expression and promoted cartilage preservation. Early inhibition of TNF- can 
provide chondroprotection and cartilage preservation by decreasing release of 
glycosaminoglycans and increasing lubricin production in the post traumatic arthritis rat 
model (Elsaid et al,2009). These results suggest that the inhibition of either or both of these 
cytokines may offer a useful therapeutic approach to the management of PTOA by reducing 
gene expression of MMPs involved in cartilage matrix degradation and favoring its repair. 
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10. Matrix protection 
Matrix protection could be achieved by either direct inhibition of matrix proteinases or by 
affecting the factors responsible for their activation, such as ROS, NO, inflammatory 
cytokines, etc. NO has been long implicated in cartilage degradation, noting that arthritic 
patients showed elevated levels of nitrites (Spreng et al,2001) and lipid peroxidation 
products (Situnayake et al,1991a,1991b) in their biological fluids. The increased NO 
production has been reported to inhibit aggrecan synthesis  (Evans et al,1995), increase 
iNOS activity, reduce proteoglycan synthesis (Jarvinen et al,1995) and increase MMP 
activity (Murrell et al,1995). Use of the iNOS inhibitor L-NIL has slowed the progression of 
PTOA in an experimental OA model in dogs (Pelletier et al,1999). It is plausible to explore 
iNOS inhibitors therapeutically for matrix protection in addition to chondroprotection. 
As a result of cartilage damage, there is a marked increase in the release of matrix 
components and their fragments, such as proteoglycans, aggrecan cleavage products, 
collagen, fibronectin, and hyaluronan fragments (Otsuki et al,2008; Ryan et al,2009; Wei et 
al,2009). Determining a profile of the released metabolites during disease progression may 
be beneficial in the development of treatment strategy and targeted therapeutic 
interventions. Specific effective inhibitors of the MMPs could also protect the matrix and in 
turn halt the disease progression. The role of MMPs has been primarily addressed in various 
OA models or in patients with signs of arthritis.  In PTOA, there is very little, if any, 
available information. Selective inhibitors are not widely available and the majority of 
studies have utilized broad spectrum MMP inhibitors, which in addition to a direct effect on 
MMPs, have been also associated with adverse musculoskeletal effects such as muscle 
stiffness, bursitis and fibrosis (Pelletier et al,2007). Studies with MMP-13 knockout mice 
(Little et al,2009) showed cartilage protection when OA was surgically induced, suggesting a 
crucial role of MMP-13 in cartilage degradation. Oral dosing of the MMP-13 inhibitor in a 
rabbit OA model has shown cartilage protection without the musculoskeletal adverse effects 
(Johnson et al,2007). These very promising but preliminary data may have potential in 
PTOA therapy, although clinical trials with several MMP inhibitors in patients with 
established OA have failed due to side effects and lack of efficacy. ADAMTS‘s have also 
been implicated in the pathogenesis of OA. The use of ADAM-TS5 knockout mice have 
shown that these mice do not develop OA (Glasson et al,2005), but display some side effects, 
such as fibrosis. Inhibitors of aggrecanases with higher specificity and lower toxicity are 
among future therapeutic agents for the treatment of PTOA.  
11. Matrix remodeling with anabolic growth factors 
One of the very important directions in the development of pharmacological interventions 
in PTOA is the ability to stimulate production of new cartilage extracellular matrix. The best 
candidates are growth factors including members of the TGF-┚ superfamily, FGFs, Insulin-
like Growth Factor (IGF)-1. Bone Morphogenetic Proteins (BMPs) belong to the TGF-┚ 
superfamily and are important stimuli of mesenchymal cell differentiation and extracellular 
matrix formation. BMP-2 and BMP-7 appear to be extremely potent in cartilage and bone 
repair. The most studied BMP for cartilage repair is BMP-7, also known as osteogenic 
protein-1 (OP-1). It has been studied most extensively in vitro in our laboratory on human 
cartilage (reviewed in (Chubinskaya et al,2007,2011) as well as in OA and PTOA animal 
models (Badlani et al,2008;Cook et al,2003;Hayashi et al,2008,2010;Hurtig et al,2009). The 
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results suggest that BMP-7 may be the best candidate for a disease-modifying OA drug and 
also for PTOA. Unlike TGF-┚ and other BMPs, BMP-7 up-regulates chondrocyte metabolism 
and protein synthesis without creating uncontrolled cell proliferation and formation of 
osteophytes. BMP-7 prevents chondrocyte catabolism induced by IL-1 or fragments of 
matrix components. It has synergistic anabolic effects with other growth factors such as IGF-
1, in addition to its anabolic effect acts as a cell survival factor (reviewed in Chubinskaya et 
al,2007). BMP-7 restores the responsiveness of human chondrocytes to IGF-1 lost with 
ageing through the regulation of IGF-1 and its signaling pathway (Chubinskaya et al,2011; 
Im et al,2003). IGF-1 has chondroprotective activity in various animal models (Fortier et 
al,2002). In our most recent studies in the acute ex vivo cartilage trauma model, BMP-7 
stimulated PG synthesis and preserved matrix integrity. Treatment with BMP-7 also 
significantly promoted cell survival in the impacted region (two-fold difference) and 
prevented expansion of cell death and matrix degeneration into the adjacent, but not 
impacted regions. BMP-7 has been also used in various PTOA animal models in dogs (Cook 
et al,2003), sheep (Hurtig et al,2009), goats (Louwerse et al,2000) and rabbits (Badlani et 
al,2008;Hayashi et al,2008,2010). In all these PTOA models (ACL transaction, osteochondral 
defect, and impaction), BMP-7 regenerated articular cartilage, increased repair tissue 
formation and improved integrative repair between new cartilage and the surrounding 
articular surface. In the impaction model (Hurtig et al,2009), a window of opportunity for 
the treatment with BMP-7 has been identified. It was found that therapeutic application of 
BMP-7 was most effective in arresting progression of cartilage degeneration if administered 
twice at weekly intervals either immediately after trauma or delayed by three weeks.  If 
delayed by three months, the treatment was ineffective, suggesting that the development 
and progression of PTOA could be arrested and maybe even prevented if the right 
treatment is administered at the right time. Phase I clinical study produced very 
encouraging results by showing tolerability to the treatment, absence of toxic response, and 
a greater symptomatic improvement in patients that received a single injection of BMP-7 
(Hunter et al,2010). Clinical efficacy of the BMP-7 treatment is currently being tested in a 
phase II clinical OA study. 
Other growth factors from the fibroblast growth factor family have been also tested as 
potential DMOADs in PTOA. FGFs are important regulators of cartilage development and 
homeostasis (Ellman et al,2008). FGF-2 can stimulate cartilage repair responses (Henson et 
al,2005), but its potent mitogenic effects may lead to chondrocyte cluster formation and 
poor extracellular matrix due to a relatively low level of type II collagen (Ellman et 
al,2008). FGF-2 has been also shown to induce pro-catabolic and pro-inflammatory 
responses (Ellman et al,2008). In a rabbit ACL transection model, sustained release 
formulations of FGF-2 reduced OA severity (reviewed in Lotz et al, 2010). Another 
member of the same family, FGF-18, has been shown to induce anabolic effects in 
chondrocytes and chondroprogenitor cells and to stimulate cell proliferation and type II 
collagen production (Ellsworth et al,2002). In a rat meniscal tear model of OA, intra-
articular FGF-18 injections induced remarkable formation of new cartilage and reduced 
the severity of experimental lesions (Moore et al,2005). Thus far, only two anabolic factors, 
FGF-18 and BMP-7, are currently being tested in clinical studies in patients with 
established OA. At this stage of our cumulative knowledge, BMP-7 appears to be one of 
the best candidate therapeutic agents for cartilage treatment after injury, since it affects 
multiple catabolic and anabolic pathways.  
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12. Conclusion 
One of the unanswered PTOA questions is when and which therapies that have been 
developed as disease-modifying OA drugs are indicated for patients with post-traumatic 
OA and whether a different set of treatments and molecular targets has to be considered. 
Through basic and clinical research an impressive progress has been made towards 
elucidation of pathogenesis of PTOA and understanding the mechanisms that govern 
immediate cellular responses to injury. However, this still requires further validation in a 
large cohort of patients with various types of joint injuries. The ideal therapy to arrest and 
prevent the development and progression of PTOA must be multi-varied and include 
anabolic effects on chondrocyte metabolism characterized by elevated intrinsic repair, while 
protecting integrity of cell membrane and inhibiting catabolic pathways that lead to 
chondrocyte death and matrix loss (Lotz et al,2010). The following are the key mechanisms 
that should constitute the basis for the design of intervention therapies: 1) 
Chondroprotection; 2) Anti-inflammatory; 3) Matrix protection; and 4) Pro-anabolic, stimuli 
of cartilage remodeling and regeneration. The most beneficial agents are those that target 
multiple pathways and mechanisms. A number of molecular targets have been identified 
(Table 1) and many of the existing therapeutic agents have been already tested in vitro and in 
vivo. The biggest remaining challenge is the translation of this knowledge into the clinic and 
the development of appropriate effective therapy/therapies administered within the 
window of opportunity. Currently, the most suitable route for administering such therapy 
appears to be intra-articular injections that allow accumulation of critical doses of the drug 
within the damaged area and also reduce the risk of systemic side effects. To monitor the 
efficacy of the PTOA therapy, an appropriate set of bio- and imaging markers is needed that 
could predict and correlate with the progression of the disease, since it takes years and 
decades for the disease to develop.   
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